Loading
PH
PRA Health Sciences, Inc. Stock: price and insider trades · United States
PRA Health Sciences, Inc.: what insiders have been doing
PRA Health Sciences, Inc., classified in the Healthcare & Pharma sector, is a listed company based in Raleigh, United States, founded in 1976. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of PRA Health Sciences, Inc. in twelve months, the latest record being from 1 July 2021.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
26
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€2M
11 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
RevenueUS$2.7B
Gross profitUS$572.1M21% margin
Net incomeUS$169.7M6.2% margin
Last declaration on 1 July 2021
Declarations26 total
5,407 sharesCommon StockSEC:0001104659-21-088346:0
1,049 sharesCommon StockSEC:0001104659-21-088358:0
14,729 sharesCommon StockSEC:0001104659-21-088343:0
7,127 sharesCommon StockSEC:0001104659-21-088359:0
46,500 sharesCommon StockSEC:0001104659-21-088371:0
34,500 sharesCommon StockSEC:0001104659-21-088376:0
9,683 sharesCommon StockSEC:0001104659-21-088348:0
3,521 sharesCommon StockSEC:0001104659-21-088352:0
4,480 sharesCommon StockSEC:0001104659-21-088361:0
6,589 shares@ US$166.4321.6% of flowCommon StockSEC:0001104659-21-087298:0
7,132 shares@ US$166.4232.6% of flowCommon StockSEC:0001104659-21-087297:0
77,425 shares@ US$11.7325.1% of flowCommon StockSEC:0001104659-21-083604:0
35,661 shares@ US$81.6157.7% of flowCommon StockSEC:0001104659-21-083610:0
4,213 shares@ US$95.9431.8% of flowCommon StockSEC:0001104659-21-083613:0
8,698 shares@ US$101.4268.2% of flowCommon StockSEC:0001104659-21-082848:0
14,000 shares@ US$75.8120.7% of flowCommon StockSEC:0001104659-21-082832:0
132,986 shares@ US$11.7342.3% of flowCommon StockSEC:0001104659-21-082830:0
250 shares0Common StockSEC:0001104659-21-076349:0
250 shares0Common StockSEC:0001104659-21-076342:0
2,823 shares0Common StockSEC:0001104659-21-076347:0
330 shares0Common StockSEC:0001104659-21-076355:0
4,823 shares0Common StockSEC:0001104659-21-076353:0
14,486 shares0Common StockSEC:0001104659-21-076359:0
250 shares0Common StockSEC:0001104659-21-076361:0
250 shares0Common StockSEC:0001104659-21-076362:0
25 of 26 declarations
About PRA Health Sciences, Inc.
PRA Health Sciences, Inc. (historical ticker: PRAH) was a U.S.-based clinical research services company and, before its acquisition, was listed on NASDAQ in the United States. For French-, Belgian- and Swiss-based investors, PRA should be understood as a contract research organization (CRO): a specialist outsourced provider that supports pharmaceutical companies, biotechnology firms and medical device makers across the clinical development process. The company was founded in 1976 and was headquartered in Raleigh, North Carolina, a major U.S. life-sciences hub. ([forbes.com](https://www.forbes.com/companies/pra-health-sciences/?utm_source=openai))
Operationally, PRA offered full-service outsourced clinical development capabilities spanning trial planning, site management, data management, biostatistics, clinical monitoring, pharmacovigilance and regulatory support. Its business model was built around serving sponsors that need help designing and executing complex clinical programs, often across multiple therapeutic areas and geographies. In the CRO industry, competitive strength typically depends on scale, therapeutic expertise, execution quality, global reach and long-standing sponsor relationships, and PRA positioned itself as a global partner rather than a niche local provider. ([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/p/NASDAQ_PRAH_2016.pdf?utm_source=openai))
Read moreShow less
Geographically, the company maintained an international footprint to support multinational studies and to meet the regulatory and operational requirements of global drug development. That breadth mattered because clinical trials are increasingly cross-border and highly regulated, making local infrastructure and global coordination critical. A defining corporate event came in 2021: ICON plc announced and then completed its acquisition of PRA Health Sciences in an approximately $12 billion cash-and-stock transaction. Following completion, PRA ceased trading as a standalone public company and was integrated into ICON. ICON described the transaction as creating a world-leading healthcare intelligence and clinical research organization. ([iconplc.gcs-web.com](https://iconplc.gcs-web.com/news-releases/news-release-details/icon-acquire-pra-health-sciences-creating-world-leader?utm_source=openai))
From an equity-analysis standpoint, the key takeaway is that PRAH is now primarily a legacy reference rather than an active standalone listed issuer. The company’s historical profile is still useful for sector comparison and for understanding the evolution of the CRO industry, but its business, clients and capabilities were absorbed into ICON as of July 1, 2021. Recent material developments are therefore centered on the acquisition and integration rather than on independent standalone reporting. For current investors, that means PRAH should be treated as a historical U.S. NASDAQ healthcare-services name, not as an ongoing independent equity story. ([iconplc.gcs-web.com](https://iconplc.gcs-web.com/news-releases/news-release-details/icon-acquisition-creates-world-leading-healthcare-intelligence/?utm_source=openai))
